Mathilde Saint-Ghislain
Overview
Explore the profile of Mathilde Saint-Ghislain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Champiat S, Salaun H, Lucibello F, Scoazec J, Besse B, Lalanne A, et al.
JCO Precis Oncol
. 2023 May;
7:e2200363.
PMID: 37224427
No abstract available.
2.
Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A
Histopathology
. 2022 Dec;
82(1):162-169.
PMID: 36482269
The diagnosis, histomolecular classes of breast cancers (luminal A, luminal B, HER2-enriched, and basal-like), and accurate prediction of prognosis are commonly determined using morphological and phenotypical analyses in clinical practice...
3.
Salaun H, De Koning L, Saint-Ghislain M, Servois V, Ramtohul T, Garcia A, et al.
Oncoimmunology
. 2022 Sep;
11(1):2116845.
PMID: 36092639
Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience...
4.
Saint-Ghislain M, Derrien A, Geoffrois L, Gastaud L, Lesimple T, Negrier S, et al.
Eur J Cancer
. 2022 Jul;
173:105-112.
PMID: 35863105
Background: MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant...
5.
Saint-Ghislain M, Levenbruck C, Bellesoeur A
Int J Womens Dermatol
. 2022 Jan;
7(5Part A):552-559.
PMID: 35024412
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic...
6.
Salaun H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Dieras V, et al.
Bull Cancer
. 2021 Nov;
109(1):76-82.
PMID: 34799081
PARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors...
7.
Aldea M, Lam L, Orillard E, Perez C, Saint-Ghislain M, Gravis G, et al.
Eur J Cancer
. 2021 Nov;
159:87-97.
PMID: 34742160
Background: Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage...
8.
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32914004
Purpose: Precision medicine trials constitute a precious source of molecular data with prospective clinical annotations allowing the exploration of patients' subpopulations according to specific clinical or biological questions. Using the...
9.
Eeckhoutte A, Saint-Ghislain M, Reverdy M, Raynal V, Baulande S, Bataillon G, et al.
Fam Cancer
. 2020 Mar;
19(3):203-209.
PMID: 32172432
CDK12 variants were investigated as a genetic susceptibility to ovarian cancer in a series of 416 unrelated and consecutive patients with ovarian carcinoma and who carry neither germline BRCA1 nor...
10.
Auvray M, Benderra M, Bretagne M, Faouzi S, Lebellec L, Majhoubi L, et al.
Bull Cancer
. 2017 Aug;
104(9):744-751.
PMID: 28826736
Since the advent of the HER2 biomarker allowing access to treatment with trastuzumab, we observe an explosion in research for biomarkers, in which the economic pressure linked to the costs...